Lakefront Biotherapeutics American Depositary Shares
LKFT
82 hedge funds and large institutions have $660M invested in Lakefront Biotherapeutics American Depositary Shares in 2024 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 28 reducing their positions, and 14 closing their positions.
23% more call options, than puts
Call options by funds: $2.49M | Put options by funds: $2.02M
0.89% more ownership
Funds ownership: 30.2% → 31.09% (+0.89%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
4% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 28
7% less funds holding
Funds holding: 88 → 82 (-6)
18% less capital invested
Capital invested by funds: $809M → $660M (-$149M)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$29.3M |
| 2 |
Millennium Management
New York
|
+$9.74M |
| 3 |
NM
Newtyn Management
New York
|
+$5.5M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.9M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.96M |
| 2 |
Morgan Stanley
New York
|
-$7.4M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.75M |
| 4 |
Citigroup
New York
|
-$2.72M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.2M |
LKFT Hedge Fund Activity: Q1 2024 in Review
82 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q1 2024, worth a combined $660M — down 18% from $809M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LKFT and 9 opened new positions — a net loss of 5 holders — while 28 trimmed existing stakes and 27 added.
The largest buyer was Deerfield Management, adding an estimated $29.3M. The largest seller was Citadel Advisors, cutting an estimated $8.96M.
- 82 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q1 2024, down from 88 in Q4 2023.
- Funds reported $660M of Lakefront Biotherapeutics American Depositary Shares stock for Q1 2024, down 18% quarter-over-quarter.
- 9 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q1 2024 and 14 closed out, a net change of -5 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q1 2024 was Deerfield Management, an estimated $29.3M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q1 2024 was Citadel Advisors, an estimated $8.96M sold.
Based on aggregated 13F filings for Q1 2024.